A Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH) - Trial NCT05649748
Access comprehensive clinical trial information for NCT05649748 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Insmed Incorporated and is currently Recruiting. The study focuses on Pulmonary Arterial Hypertension. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Insmed Incorporated
Timeline & Enrollment
Phase 2/3
Feb 28, 2023
Dec 31, 2026
Primary Outcome
Number of Participants Who Experience at Least one Treatment Emergent Adverse Event (TEAE) and TEAEs by Severity
Summary
The primary purpose of the study is to evaluate the safety and tolerability of the long-term
 use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202
 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05649748
Non-Device Trial